Terapias de purificación sanguínea en COVID-19

Palabras clave: COVID-19,sepsis, SARS-CoV-2, citosinas, insuficiencia renal, neumonía (DeCS).

Resumen

Introducción: el COVID-19 es una enfermedad causada por un nuevo beta coronavirus (SARS-CoV-2), cuyo espectro incluye casos severos con neumonía y complicaciones sistémicas que se dan como consecuencia de una liberación exagerada de mediadores inflamatorios conocida como “tormenta de citoquinas”. En este tipo de pacientes las terapias de purificación sanguínea, incluyendo la hemoadsorción y la terapia plasmática podrían tener un beneficio clínico importante y evitar las complicaciones como disfunción multiorgánica y muerte.

Objetivo: revisar toda la literatura disponible acerca de las terapias de purificación sanguínea y sus beneficios en los pacientes con COVID-19.

Materiales y métodos: se realizó una búsqueda de la literatura en las bases de datos ClinicalKey, Embase, PubMed y Ovid con los términos “COVID-19”, “sepsis”, “SARS-CoV-2”, “citosinas”, “insuficienciencia renal”, “neumonía”.

Resultados: se encontraron 246 referencias y luego de aplicar los filtros, se seleccionaron 61 publicaciones con contenido relevante para la presente revisión.

Conclusión: teniendo en cuenta su gran evidencia científica en el manejo de la tormenta de citoquinas en otros escenarios, las terapias de purificación sanguínea, que incluyen técnicas difusivas, convectivas, de hemoadsorción y terapia plasmática, pueden ser herra- mientas de tratamiento muy prometedoras en pacientes con COVID-19.

Descargas

La descarga de datos todavía no está disponible.

Referencias

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-44. https://doi.org/10.1038/ s41564-020-0695-z.

Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. 2020;2(7):E428-36. https://doi.org/10.1016/S2665-9913(20)30120-X.

World Health Organization (WHO). Coronavirus disease 2019 (COVID-19): situation report, 51. Geneva: WHO; 2020.

Colombia. Ministerio de Salud y Protección Social (Minsalud). Colombia confirma su primer caso de COVID-19. Boletín de Prensa No. 050 de 2020. Bogotá D.C.: MinSalud; 2020 [citado Jul 12 2020 Jul]. Disponible en: https://www.minsalud.gov.co/Paginas/Colombiaconfirma-su-primer-caso-de-COVID-19.aspx.

World Health Organization (WHO). Coronavirus disease (COVID-19) outbreak situation. Geneva: WHO; 2020.

Colombia. Ministerio de Salud y Protección social (Minsalud). Coronarivus (COVID-19). Bogotá D.C.: Minsalud; 2020 [citado Jul 12 2020 Jul]. Disponible en: https://d2jsqrio60m94k.cloudfront.net/.

van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARSCoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564-7. https://doi.org/10.1056/NEJMc2004973.

Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical characteristics of 3062 COVID-19 patients: a meta-analysis. J Med Virol. 2020. https://doi.org/10.1002/jmv.25884.

Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-9. https://doi.org/10.1001/jama.2020.6775.

Shang J, Ye G, Shi K, Wan Y, Luo C,Aihara H, et al. Structural basis of receptorrecognition by SARS-CoV-2. Nature. 2020;581(7807):221- 4. https://doi.org/10.1038/s41586-020-2179-y.

Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473-4. https://doi.org/10.1126/science.abb8925.

Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529-39. https://doi.org/10.1007/s00281-017-0629-x.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologicalfeatures of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-9. https://doi.org/10.1172/JCI137244.

Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-8. https://doi.org/10.1007/s00134-020-05991-x.

Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting Interleukin-6 Signaling in Clinic. Immunity. 2019;50(4):1007-23. https://doi.org/10.1016/j.immuni.2019.03.026.

Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959-70. https://doi.org/10.2217/imt-2016-0020.

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):1-11. https://doi.org/10.1001/ jamainternmed.2020.0994.

Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, et al. Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54(8):2568-76. https://doi.org/10.1002/art.22018.

Schwindenhammer V, Girardot T, Chaulier K, Grégoire A, Monard C, Huriaux L, et al. oXiris® Use in Septic Shock: Experience of Two French Centres. Blood Purif. 2019;47(Suppl 3):1-7. https://doi.org/10.1159/000499510.

Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID19. Kidney Int. 2020;97(5):829-38. https://doi.org/10.1016/j.kint.2020.03.005.

Antonini V. Acute Kidney Injury in COVID-19 Patients. European Society of Intensive Care Medicine; 2020.

Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med. 2020;8(7):P738- 42. https://doi.org/10.1016/S2213-2600(20)30229-0.

Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-8. https://doi.org/10.1016/S0140-6736(20)30937-5.

Larsen CP, Bourne TD, Wilson JD, Saqqa O, Sharshir MA. Collapsing Glomerulopathy in a Patient With COVID-19. Kidney Int Rep. 2020;5(6):935-9. https://doi.org/10.1016/j.ekir.2020.04.002.

Su H, Yang M, Wan C, Yi L-X, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98(1):219-27. https://doi.org/10.1016/j.kint.2020.04.003.

González C, Yama E, Yomayusa N, Vargas J, Rico J, Ariza A, et al. Consenso colombiano de expertos sobre recomendaciones informadas en la evidencia para la prevención, diagnóstico y manejo de la lesión renal aguda por SARS-CoV-2/COVID-19. Rev Colomb Nefrol 2020;7(Supl 2). https://doi.org/10.22265/acnef.7.Suplemento.473.

Molina-Andújar A, Blasco M, Poch E. Papel de la diálisissostenida de baja eficiencia en las unidades de cuidadosintensivos. Nefrología. 2019;39(1):98-9. https://doi.org/10.1016/j.nefro.2018.06.002.

Aggarwal S, García-Tellez N, Aggarwal G, Lavie C, Lippi G, Henry BM. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States. Diagnosis (Berl). 2020;7(2):91-6. https://doi.org/10.1515/dx-2020-0046.

Li Z, Wu M, Yao J, Guo J, Liao X, Song S, et al. Caution on Kidney Dysfunctions of COVID-19 Patients. medRxiv. 2020. https://doi.org/10.1101/2020.02.08.20021212.

Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, et al. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. J Am Soc Nephrol. 2020;31(6):1157-65. https://doi.org/10.1681/ASN.2020030276.

Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D. Hemofiltration in human sepsis: Evidence for elimination of immunomodulatory substances. Kidney Int. 1995;48(5):1563-70. https://doi.org/10.1038/ki.1995.448.

Joannes-Boyau O, Rapaport S, Bazin R, Fleureau C, Janvier G. Impact of High Volume Hemofiltration on Hemodynamic Disturbance and Outcome during Septic Shock: ASAIO J. 2004;50(1):102-9. https://doi.org/10.1097/01.mat.0000104846.27116.ea.

Berhés M, Fábián Á, László I, Végh T, Molnár C, Fülesdi B, et al. [Organ Replacement Therapy and Life-Supporting Treatment Modalities in Critically Ill COVID-19 Patients]. Orv Hetil. 2020;161(17):704-9. https://doi.org/10.1556/650.2020.31813.

Angus DC, van der Poll T. Severe Sepsis and Septic Shock. N EnglJ Med. 2013;369(9):840-51. https://doi.org/10.1056/NEJMra1208623.

Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, et al. Interpreting the Mechanisms of Continuous Renal Replacement Therapy in Sepsis: The Peak Concentration Hypothesis. Artif Organs. 2003;27(9):792-801. https://doi.org/10.1046/j.1525-1594.2003.07289.x.

Peng ZY, Wang HZ, Carter MJ, Dileo MV, Bishop JV, Zhou FH, et al. Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. Kidney Int. 2012;81(4):363-9. https://doi.org/10.1038/ki.2011.320.

Ronco C, Bellomo R, Kellum JA, Ricci Z. Critical care nephrology. Elsevier; 2019 [citado May 31 2020]. Disponible en: http://ezproxy.usherbrooke.ca/login?url=https://www.clinicalkey.com/#!/browse/book/3-s2.0-C20150004129.

Borthwick EM, Hill CJ, Rabindranath KS, Maxwell AP, McAuley DF, Blackwood B. High-volume haemofiltration for sepsis in adults.Cochrane Emergency and Critical Care Group, editor. Cochrane Database Syst Rev. 2017;31(1):CD008075. https://doi.org/10.1002/14651858.CD008075.pub3.

Joannes-Boyau O, Honoré PM, Perez P, Bagshaw SM, Grand H, Canivet J-L, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med. 2013;39(9):1535-46. https://doi.org/10.1007/s00134-013-2967-z.

Chinese Medical Association. Expert consensus on the Application of Special Blood purification Technology in severe COVID-19 pneumonia. 2020 [citado 2020 Jul 12]. Disponible en: https://www.era-edta.org/en/wp-content/uploads/2020/03/English-version-Expertconsensus-on-the-Application-of-Special-Blood-purification-Technology-in-severe-COVID-19-pneumonia.pdf

Yang XH, SunRH, Zhao MY, Chen EZ, Liu J, Wang HL, et al. Expert recommendations on blood purification treatment protocol for patients with severe COVID-19:. Chronic Dis Transl Med. 2020;6(2):106-114. https://doi.org/10.1016/j.cdtm.2020.04.002.

Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia. N Engl J Med. 1997;336(4):243-50. https://doi.org/10.1056/NEJM199701233360402.

Haase M, Bellomo R, Baldwin I, Haase-Fielitz A, Fealy N, Davenport P, et al. Hemodialysis Membrane With a High-Molecular-Weight Cutoff and Cytokine Levelsin Sepsis Complicated byAcuteRenal Failure: APhase 1 Randomized Trial.Am J Kidney Dis. 2007;50(2):296- 304. https://doi.org/10.1053/j.ajkd.2007.05.003.

Honore PM, Jacobs R, Joannes-Boyau O, De Regt J, De Waele E, van Gorp V, et al. Newly Designed CRRT Membranes for Sepsis and SIRS—A Pragmatic Approach for Bedside Intensivists Summarizing the More Recent Advances: A Systematic Structured Review. ASAIO J. 2013;59(2):99-106. https://doi.org/10.1097/MAT.0b013e3182816a75.

Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early Use of Polymyxin B Hemoperfusion in Abdominal Septic Shock: The EUPHAS Randomized Controlled Trial. JAMA. 2009;301(23):2445-52. https://doi.org/10.1001/jama.2009.856.

Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11(2):R47. https://doi.org/10.1186/cc5780.

Cantaluppi V, Assenzio B, Pasero D, Romanazzi GM, Pacitti A, Lanfranco G, et al. Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med. 2008;34(9):1638-45. https://doi.org/10.1007/s00134-008-1124-6.

Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et al. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. JAMA. 2018;320(14):1455-63. https://doi.org/10.1001/jama.2018.14618.

Rathkamp M, Tomicic V, Cornejo J, Cruz P. Adsorción extracorpórea de citoquinas en el tratamiento del shock séptico refractario. Casos clínicos. Rev. Méd. Chile. 2018;146(6):796-801. https://doi.org/10.4067/s0034-98872018000600796.

Napp LC, Ziegeler S, Kindgen-Milles D. Rationale of Hemoadsorption during Extracorporeal Membrane Oxygenation Support. Blood Purif. 2019;48(3):203-14. https://doi.org/10.1159/000500015.

Cytosorbents Inc.: Instructions for use, Document Number 17-0071-14.

Honore PM, Hoste E, Molnár Z, Jacobs R, Joannes-Boyau O, Malbrain MLNG, et al. Cytokine removal in human septic shock: Where are we and where are we going? Ann. Intensive Care. 2019;9(1):56. https://doi.org/10.1186/s13613-019-0530-y.

Mehta Y, Mehta C, Kumar A, George JV, Gupta A, Nanda S, et al. Experience with hemoadsorption (CytoSorb ®) in the management of septic shock patients. World J Crit Care Med. 2020;9(1):1-12. https://doi.org/10.5492/wjccm.v9.i1.1.

Friesecke S, Träger K, Schittek GA, Molnar Z, Bach F, Kogelmann K, et al. International registry on the use of the CytoSorb® adsorber in ICU patients: Study protocol and preliminary results. Med Klin Intensivmed Notfallmed. 2019;114(8):699-707. https://doi.org/10.1007/s00063-017-0342-5.

Singh A, Mehta Y, Trehan N. Bilirubin Removal Using CytoSorb Filter in a Cardiac Surgical Patient. J Cardiothorac Vasc Anesth. 2019;33(3):881-3. https://doi.org/10.1053/j.jvca.2018.08.213.

Poli EC, Alberio L, Bauer-Doerries A, Marcucci C, Roumy A, Kirsch M, et al. Cytokine clearance with CytoSorb® during cardiac surgery: a pilot randomized controlled trial. Crit Care. 2019;23(1):108. https://doi.org/10.1186/s13054-019-2399-4.

Monard C, Rimmelé T, Ronco C. Extracorporeal Blood Purification Therapies for Sepsis. Blood Purif. 2019;47(Suppl 3):1-14. https://doi.org/10.1159/000499520.

Ronco C, Reis T, De Rosa S. Coronavirus Epidemic and Extracorporeal Therapies in Intensive Care: Si vis pacem para bellum. Blood Purif 2020;49(3):255-8. https://doi.org/10.1159/000507039.

Nguyen TC, Carcillo JA. Bench-to-bedside review: Thrombocytopenia-associated multiple organ failure - a newly appreciated syndrome in the critically ill. Crit Care. 2006;10(6):235. https://doi.org/10.1186/cc5064.

Chang JC. Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease. Thromb J. 2019;17(1):10. https://doi.org/10.1186/s12959-019-0198-4.

Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care. 2020;24(1):128. https://doi.org/10.1186/s13054-020-2836-4.

Publicado
2020-06-18
Cómo citar
1.
Daza Arnedo R, Aroca Martínez G, Rico Fontalvo JE, Rey Vela E, Pájaro Galvis N, Salgado Montiel LG, Monterrosa Robles MC, Pérez Calvo C, Portela Buelvas K. Terapias de purificación sanguínea en COVID-19. Rev. Colomb. Nefrol. [Internet]. 18 de junio de 2020 [citado 28 de octubre de 2020];7(Supl.2). Disponible en: https://revistanefrologia.org/index.php/rcn/article/view/476